BACKGROUND: Despite the high incidence of acute stroke, only a minority of patients are enrolled in acute stroke treatment trials. We aimed to identify factors associated with participation in clinical trials of novel therapeutic agents for acute stroke. METHODS: Prospective survey of patients with acute stroke <72 hours from onset. A structured interview was administered to the patient or primary decision-maker. If offered participation in an actual acute treatment trial, questions focused on decisions about that trial; otherwise a similar mock trial was proposed. The primary outcome was whether the subject agreed to participate in the proposed trial. RESULTS: A total of 200 subjects (47% patients, 53% proxies) completed the survey: mean age 63 +/- 14 years, 47% women, 44% white, 50% black. A real acute trial was offered to 22%; others were offered a mock trial. Overall, 57% (95% confidence interval: 50%-64%) of respondents stated they would participate in the proposed acute treatment trial. There were no differences with respect to age, sex, race, educational level, self-assessed stroke severity or stroke type, vascular risk factors, or comorbidities. Misconceptions about key research concepts were found in 50% but did not impact participation. Participation was associated with the perceived risk of the proposed trial intervention (p < 0.001), prior general attitudes about research (p < 0.001), and influences attributed to family, religion, and other personal beliefs (p < 0.001). Patients were more likely to participate than proxy decision-makers (p = 0.04). CONCLUSIONS: Demographic factors, clinical factors, and prior knowledge about research have little impact on the decision to participate in acute stroke clinical trials. Preexisting negative attitudes and external influences about research strongly inhibit participation. Patients are more inclined to participate than their proxy decision-makers.
BACKGROUND: Despite the high incidence of acute stroke, only a minority of patients are enrolled in acute stroke treatment trials. We aimed to identify factors associated with participation in clinical trials of novel therapeutic agents for acute stroke. METHODS: Prospective survey of patients with acute stroke <72 hours from onset. A structured interview was administered to the patient or primary decision-maker. If offered participation in an actual acute treatment trial, questions focused on decisions about that trial; otherwise a similar mock trial was proposed. The primary outcome was whether the subject agreed to participate in the proposed trial. RESULTS: A total of 200 subjects (47% patients, 53% proxies) completed the survey: mean age 63 +/- 14 years, 47% women, 44% white, 50% black. A real acute trial was offered to 22%; others were offered a mock trial. Overall, 57% (95% confidence interval: 50%-64%) of respondents stated they would participate in the proposed acute treatment trial. There were no differences with respect to age, sex, race, educational level, self-assessed stroke severity or stroke type, vascular risk factors, or comorbidities. Misconceptions about key research concepts were found in 50% but did not impact participation. Participation was associated with the perceived risk of the proposed trial intervention (p < 0.001), prior general attitudes about research (p < 0.001), and influences attributed to family, religion, and other personal beliefs (p < 0.001). Patients were more likely to participate than proxy decision-makers (p = 0.04). CONCLUSIONS: Demographic factors, clinical factors, and prior knowledge about research have little impact on the decision to participate in acute stroke clinical trials. Preexisting negative attitudes and external influences about research strongly inhibit participation. Patients are more inclined to participate than their proxy decision-makers.
Authors: A Furlan; R Higashida; L Wechsler; M Gent; H Rowley; C Kase; M Pessin; A Ahuja; F Callahan; W M Clark; F Silver; F Rivera Journal: JAMA Date: 1999-12-01 Impact factor: 56.272
Authors: Katie B McClure; Nicole M DeIorio; Mary D Gunnels; Maria J Ochsner; Michelle H Biros; Terri A Schmidt Journal: Acad Emerg Med Date: 2003-04 Impact factor: 3.451
Authors: Scott D Halpern; Jason H T Karlawish; David Casarett; Jesse A Berlin; Raymond R Townsend; David A Asch Journal: Am Heart J Date: 2003-12 Impact factor: 4.749
Authors: Giselle Corbie-Smith; Catherine M Viscoli; Walter N Kernan; Lawrence M Brass; Philip Sarrel; Ralph I Horwitz Journal: J Clin Epidemiol Date: 2003-04 Impact factor: 6.437
Authors: Carrie A Sims; Joshua A Isserman; Daniel Holena; Latha Mary Sundaram; Nikolai Tolstoy; Sarah Greer; Seema Sonnad; Jose Pascual; Patrick Reilly Journal: J Trauma Acute Care Surg Date: 2013-01 Impact factor: 3.313
Authors: Dorothy F Edwards; Ravi Menon; Ali Fokar; Christopher Gibbons; Jeffrey Wing; Brisa Sanchez; Chelsea S Kidwell Journal: J Health Care Poor Underserved Date: 2013-02
Authors: William B Feldman; Anthony S Kim; S Andrew Josephson; Daniel H Lowenstein; Winston Chiong Journal: Neurology Date: 2016-03-23 Impact factor: 9.910
Authors: Kara K Patterson; Nicole Gallant; Tracey Ormiston; Chad Patience; Mandy Whitechurch; Avril Mansfield; Janet Brown Journal: Physiother Can Date: 2015-08 Impact factor: 1.037
Authors: Tatiana Greige; Casey Norton; Lydia D Foster; Sharon D Yeatts; Andre Thornhill; Jessica Griffin; Jeffrey Wang; Courtney M Hrdlicka; Magdy Selim Journal: Stroke Date: 2021-01-25 Impact factor: 7.914